The Doctor’s Voice by Dr. Pietro Emanuele Garbelli Offers Groundbreaking Solutions to Minimizing Medical Burnout and Transforming the Future of Healthcare

Doctors leaving the medical profession is a global problem that can no longer be ignored. Dr. Pietro Emanuele Garbelli’s The Doctor’s Voice is an empowering medical thought leadership book that presents innovative, game-changing solutions doctors can use to manage stress, achieve peak performance, and be the essential voice healthcare organizations need to thrive.

Dr. Pietro Emanuele Garbelli is the award-winning author of The Doctor’s Voice: Empowering Solutions to Physicians’ Frustrations, Burnout, and Healthcare Inefficiencies, a compelling and practical guide designed to empower doctors to speak up, collaborate, and thrive.

A specialist in Acute Internal Medicine, clinical director, and Thriving Healthcare Consultant, Pietro has witnessed and experienced first-hand the inefficiencies, frustrations and struggles that patients, relatives and providers have with the current healthcare system, and uses lessons learned to provide medical thought leadership. By fostering a successful collaboration between empowered physicians and healthcare stakeholders, he aims to contribute towards creating high-quality, sustainable healthcare for all.

This one-on-one interview shares Dr Pietro Emanuele Garbelli’s background and experience in writing The Doctor’s Voice: Empowering Solutions to Physicians’ Frustrations, Burnout, and Healthcare Inefficiencies.

Tell us about The Doctor’s Voice: Empowering Solutions to Physicians’ Frustrations, Burnout, and Healthcare Inefficiencies.

Doctors leaving the medical profession is a global problem that can no longer be ignored. The COVID-19 pandemic has exacerbated burnout for physicians and administrators alike, and it is clear the healthcare industry as a whole is broken.

The Doctor’s Voice is an informative and practical book that offers the prescription we need to address this crisis. The book presents a comprehensive understanding of the common sources of physicians’ frustrations and illuminates a path to empower doctors to use their voices as vital feedback, ultimately boosting engagement, productivity, and retention. It is a blueprint that organizations can use to build engagement and trust across the spectrum of healthcare stakeholders to create thriving healthcare. It is an eye-opener for individuals in the healthcare industry and a must-read for those seeking to improve overall well-being and performance.

What inspired you to write The Doctor’s Voice: Empowering Solutions to Physicians’ Frustrations, Burnout, and Healthcare Inefficiencies?

As a medical professional, I witnessed firsthand the detrimental effects of stress, burnout and declining mental and emotional well-being on physicians, and how this impacted the quality of healthcare they provided. I could see there was an increasing trend of doctors moving from job to job, going part-time, taking extended sick leave, retiring early, leaving the profession altogether, and, in the worst cases, committing suicide.I no longer wanted to be a passive observer of what was happening.

I felt called to raise awareness about these critical issues, shed light on their underlying causes, and offer empowering solutions. In The Doctor’s Voice, I break down the complexity of the current healthcare environment, revealing the unexpected consequences of physician struggles while addressing healthcare inefficiencies and proposing practical strategies for creating efficient healthcare delivery.

My aim is to create a dialogue between doctors and other healthcare stakeholders to spark change across the healthcare industry as a whole.

How did your background and experience influence your writing?

For years, I felt trapped working in an environment that did not proactively solve the issues that prevented me from doing my job well. Despite my attempts to speak out and be a part of the solution, I felt silenced, ignored, and irrelevant.Having reached the peak of my frustrations, I found myself at a crossroads between leaving my profession and investing time, energy, and money working with my coach to clarify what I could do to make a significant difference—not only for fellow struggling doctors, but also for the medical profession as a whole.I worked one-on-one with my coach during week-long retreats to obtain a clear and accurate view of the challenges I and fellow physicians faced. It was during this work that I realized that writing a book would be a wonderful way to share my insights, reach physicians around the world, and create a movement that empowers doctors to be at the forefront of healthcare improvement.As a part of writing the book, I gathered relevant data, identified reviewers, and wrote and synthesized my experience and knowledge to present the readers with an informative and actionable guide readers from all backgrounds and experience could use to create valuable and meaningful change within the industry.

What is one message you would like readers to remember?

I wrote The Doctor’s Voice to educate, inspire, and move healthcare professionals, policymakers, and organizations into action to address the underlying causes of physician burnout and professional exodus. As the issues physicians face affect everyone involved in providing healthcare, my goal is to work collaboratively with all healthcare stakeholders to create a more efficient and supportive environment where doctors can thrive and provide excellent care.

Purchasing the Book

The Doctor’s Voice: Empowering Solutions to Physicians’ Frustrations, Burnout, and Healthcare Inefficiencies is available for sale on Amazon, Barnes & Noble, Apple iBooks, Kobo, Nook, Google Play and other online bookstores. Readers are encouraged to purchase their copy today: https://www.amazon.com/Doctors-Voice-Empowering-Frustrations-Inefficiencies-ebook/dp/B0BV244569/

Connect with Dr. Pietro Emanuele Garbelli:

https://drgarbelli.com

https://twitter.com/DrGarbelli

https://www.instagram.com/drgarbelli/

https://www.facebook.com/DrGarbelli

Media Contact
Company Name: Author News Network
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: authornewsnetwork.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: The Doctor\’s Voice by Dr. Pietro Emanuele Garbelli Offers Groundbreaking Solutions to Minimizing Medical Burnout and Transforming the Future of Healthcare

Invasive Candidiasis Market and Epidemiology 2032: Treatment Market, Therapies, Companies, FDA Approvals, Epidemiology and Forecast by DelveInsight | Cidara Therapeutics Inc., Mundipharma, Astellas

The Invasive Candidiasis Market Forecast report offers an in-depth understanding of the Invasive Candidiasis, historical and forecasted epidemiology as well as the Invasive Candidiasis market trends in the 7MM.

DelveInsight’s “Invasive Candidiasis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Invasive Candidiasis, historical and forecasted epidemiology as well as the Invasive Candidiasis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

To Know in detail about the Invasive Candidiasis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Invasive Candidiasis Market Forecast

 

Some of the key facts of the Invasive Candidiasis Market Report: 

  • The Invasive Candidiasis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • In January 2024, Napp Pharmaceuticals’ latest antifungal remedy for invasive candidiasis, Rezzayo (rezafungin), has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA). Invasive candidiasis, a fungal infection triggered by the yeast candida, can impact critical bodily regions like the blood and vital organs.
  • In October 2023, Mundipharma and Cidara Therapeutics (Nasdaq: CDTX) have revealed that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has rendered a favorable opinion for rezafungin (rezafungin acetate) in the treatment of invasive candidiasis among adults.
  • According to a study by CDC [2020], candidemia is one of the most common bloodstream infections in the United States. During 2013–2017, the average incidence (rate of new infections) was approximately 9 per 100,000 people; however, this number varies substantially by geographic location and patient population
  • According to a study by Frederic et al. [2018], incidence of IC in the US cities dropped from 14.1 and 30.9 cases per 100 000 persons to 9.5 and 14.4/100 000, a decline of 33% and 54%, respectively, over the 5 year period between 2008 and 2013
  • Key Invasive Candidiasis Companies: Cidara Therapeutics Inc., Mundipharma, BREXAFEMME, Astellas Pharma, Pfizer, Gilead Sciences, Merck Sharp & Dohme, Vicuron Pharma, and others
  • Key Invasive Candidiasis Therapies: Rezafungin, Scynexis, Micafungin, Anidulafungin, AmBisome, Caspofungin, Fluconazole, and others
  • The Invasive Candidiasis epidemiology based on gender analyzed that pediatric and geriatric populations are more affected by Invasive Candidiasis than adults
  • The Invasive Candidiasis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Invasive Candidiasis pipeline products will significantly revolutionize the Invasive Candidiasis market dynamics.

 

Invasive Candidiasis Overview

Invasive candidiasis is a serious fungal infection caused by the yeast Candida species, most commonly Candida albicans. It occurs when the Candida yeast enters the bloodstream and spreads throughout the body, affecting various organs and tissues. Invasive candidiasis can be life-threatening, particularly in individuals with weakened immune systems or underlying medical conditions.

 

Get a Free sample for the Invasive Candidiasis Market Report 

https://www.delveinsight.com/sample-request/invasive-candidiasis-market

 

Invasive Candidiasis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Invasive Candidiasis Epidemiology Segmentation:

The Invasive Candidiasis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Invasive Candidiasis
  • Prevalent Cases of Invasive Candidiasis by severity
  • Gender-specific Prevalence of Invasive Candidiasis
  • Diagnosed Cases of Episodic and Chronic Invasive Candidiasis

 

Download the report to understand which factors are driving Invasive Candidiasis epidemiology trends @ Invasive Candidiasis Epidemiology Forecast

 

Invasive Candidiasis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Invasive Candidiasis market or expected to get launched during the study period. The analysis covers Invasive Candidiasis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Invasive Candidiasis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Invasive Candidiasis Therapies and Key Companies

  • Rezafungin: Cidara Therapeutics Inc./ Mundipharma
  • Scynexis: BREXAFEMME

 

Discover more about therapies set to grab major Invasive Candidiasis market share @ Invasive Candidiasis Treatment Market

 

Invasive Candidiasis Market Drivers

  • Many pharmaceutical companies are continuously researching and innovating the treatment regimens for eradicating the current unmet needs in invasive candidiasis .
  • The increasing prevalence of invasive candidiasis , for instance, knee pain associated with osteoarthritis, is primarily contributed by the increase in the aging population that will likely impact the market in the near future

 

Invasive Candidiasis Market Unmet Needs

  • Challenges in diagnoses
  • Development of novel therapies
  • Limitations in gene therapy
  • Poor disease understanding
  • Clinical biomarkers

 

Scope of the Invasive Candidiasis Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Invasive Candidiasis Companies: Cidara Therapeutics Inc., Mundipharma, BREXAFEMME, Astellas Pharma, Pfizer, Gilead Sciences, Merck Sharp & Dohme, Vicuron Pharma, and others
  • Key Invasive Candidiasis Therapies: Rezafungin, Scynexis, Micafungin, Anidulafungin, AmBisome, Caspofungin, Fluconazole, and others
  • Invasive Candidiasis Therapeutic Assessment: Invasive Candidiasis current marketed and Invasive Candidiasis emerging therapies
  • Invasive Candidiasis Market Dynamics: Invasive Candidiasis market drivers and Invasive Candidiasis market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Invasive Candidiasis Unmet Needs, KOL’s views, Analyst’s views, Invasive Candidiasis Market Access and Reimbursement 

 

To know more about Invasive Candidiasis companies working in the treatment market, visit @ Invasive Candidiasis Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Invasive Candidiasis Market Report Introduction

2. Executive Summary for Invasive Candidiasis

3. SWOT analysis of Invasive Candidiasis

4. Invasive Candidiasis Patient Share (%) Overview at a Glance

5. Invasive Candidiasis Market Overview at a Glance

6. Invasive Candidiasis Disease Background and Overview

7. Invasive Candidiasis Epidemiology and Patient Population

8. Country-Specific Patient Population of Invasive Candidiasis 

9. Invasive Candidiasis Current Treatment and Medical Practices

10. Invasive Candidiasis Unmet Needs

11. Invasive Candidiasis Emerging Therapies

12. Invasive Candidiasis Market Outlook

13. Country-Wise Invasive Candidiasis Market Analysis (2019–2032)

14. Invasive Candidiasis Market Access and Reimbursement of Therapies

15. Invasive Candidiasis Market Drivers

16. Invasive Candidiasis Market Barriers

17.  Invasive Candidiasis Appendix

18. Invasive Candidiasis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Invasive Candidiasis Market and Epidemiology 2032: Treatment Market, Therapies, Companies, FDA Approvals, Epidemiology and Forecast by DelveInsight | Cidara Therapeutics Inc., Mundipharma, Astellas

Groundbreaking New Book “IRREPLACEABLE” Reveals the Secret to Thriving in the Age of AI

Groundbreaking New Book "IRREPLACEABLE" Reveals the Secret to Thriving in the Age of AI

Miami, Florida – April 15th, 2024 – As artificial intelligence (AI) is rapidly transforming every aspect of peoples’ lives, most of them are left wondering how to adapt and succeed. Enter “IRREPLACEABLE: The Art of Standing Out in an Era of Artificial Intelligence,” the highly anticipated book by award-winning AI expert Pascal Bornet, which offers a practical roadmap for how individuals, parents, workers, and organizations can not only survive but thrive with AI. The book is now available on pre-sale and poised to become the definitive guide for navigating the AI revolution.

“AI is not here to replace us, but to challenge us to be more human,” says Bornet. “By becoming IRREPLACEABLE, we can create a future where humans and AI work together harmoniously to solve the world’s greatest challenges.”

Drawing on 20 years of pioneering research at the human-AI frontier, Bornet argues that the key to success in the age of AI is to focus on developing the uniquely human capabilities that machines cannot replicate: the “Humics.”

The book also introduces the groundbreaking IRREPLACEABLE framework and guides readers to master “The Three Competencies of the Future” for success in the AI era. Readers will also discover how to:

  • Elevate one’s work performance by leveraging AI, without losing the job to automation.
  • Safeguard and nurture children in a digital age, preparing them to thrive alongside AI.
  • Develop uniquely human abilities that complement AI’s capabilities, fostering unique human-AI synergies.
  • Transform one’s business into a model of efficiency and innovation, while building trust and differentiating on the market.
  • Recognize AI’s potential threats and apply strategies to protect oneself, loved ones, and our shared humanity in a world increasingly dominated by machines.

Advance praise for “IRREPLACEABLE” has been resounding. According to Arianna Huffington, the book is “An essential reading for anyone who cares about the future of work.” The book has already generated significant buzz and is poised to become a major publishing event.

Pascal Bornet is an award-winning expert, author, and keynote speaker on artificial intelligence and automation. He has received numerous accolades for his work and is consistently ranked as one of the top 10 AI and automation influencers globally. Bornet has also served as a senior executive at McKinsey and EY, where he founded and led their global AI and automation practices.

“IRREPLACEABLE: The Art of Standing Out in an Era of Artificial Intelligence,” published by Wiley, is available on pre-sale in all major physical and online bookstores, and on Amazon:

https://www.amazon.com/IRREPLACEABLE-Art-Standing-Artificial-Intelligence/dp/1394264402

Media Contact
Company Name: Pascaline Therias
Contact Person: Media Relations
Email: Send Email
Phone: +1 415.808.9475
City: Miami
State: FL
Country: United States
Website: www.amazon.com/IRREPLACEABLE-Art-Standing-Artificial-Intelligence/dp/1394264402

Chongqing Zhihe Bio-Pharmaceutical Co.,Ltd. appeared at the In-cosmetics Global 2024 to appreciate the functional aesthetics of Chinese ceramides

With the rapid development of the global cosmetics industry, the innovation and application of raw materials have become key issues in the industry. In-cosmetics Global 2024 opened grandly in Paris, France from 4.16 to 4.18. Chongqing Zhihe Bio-Pharmaceutical Co., Ltd. (hereinafter referred to as Zhihe Bio-Pharmaceutical), as the leader of Chinese ceramides raw materials, will witness the debut of “China Intelligent Manufacturing, Chinese Raw Materials” on the international stage.

As a high-tech enterprise driven by technology & R&D, Zhihe Bio-Pharmaceutical has successfully produced and is developing 4 kinds of sphingosine, 12 kinds of ceramides, and 5 kinds of ceramide liposomes, forming one of the rich and highly competitive ceramides product pipelines, based on years of research and exploration in synthetic biology, cosmetic application technology, and medicine technology development. 

Zhihe Bio-Pharmaceutical has achieved domestic independent research and development and mass production of phytosphingosine through technical means such as strain construction, mutagenesis, and screening. What’s more worth mentioning is that Zhihe Bio-Pharmaceutical’s ceramides series products have reached the forefront of the industry in terms of purity, content and stability, providing differentiated quality solutions according to customers’ specific needs, ensuring that the performance and effect of the product are maximized, creating a new ecosystem for the industrialization and commercialization of ceramides.

Following the debut of Zhihe Bio-Pharmaceutical’s disruptive new product- – liquid crystal bionic structure ceramide at PCHI 2024, it will also appear on the international stage this time. This is a disruptive and innovative result of Zhihe Bio-Pharmaceutical research integrating top expert resources in the industry. The launch of this innovative product not only demonstrates Zhihe Bio-Pharmaceutical’s profound heritage and forward-looking vision in the field of ceramides, but also brings new development opportunities to the entire cosmetics industry.

With its first-class R&D and production capabilities of ceramides raw materials, Zhihe Bio-Pharmaceutical Co. reflects its unremitting pursuit of innovation and quality. In the future, Zhihe Bio-Pharmaceutical Co. will continue to uphold the mission of “Biotechnology driving high-quality and better life for humanity”, lead the efficacy aesthetics of ceramides, witness the multi-dimensional strength of Chinese ceramides, promote the research and application process of ceramides and other active compounds, and contribute more to the prosperous development of the beauty industry.

Media Contact
Company Name: Chongqing Zhihe Bio-Pharmaceutical Co.,Ltd.
Contact Person: Michael Gong / Huiqi Yang
Email: Send Email
Phone: 86 13718811639 / 86 13368277777
Country: China
Website: http://www.zhswyy.com

Stellar maps quality of connectivity on major EU roads, generating 40 million data points with leading European car manufacturer

Stellar maps quality of connectivity on major EU roads, generating 40 million data points with leading European car manufacturer
Stellar has secured a significant commercial contract with a European car manufacturer to map the quality of connectivity on major European roads across several countries.

Luxembourg – 15 April, 2024 – Stellar has secured a significant commercial contract with a European car manufacturer to map the quality of connectivity on major European roads across several countries. This STEER SURVEY mapping has been completed for more than 10,000 Km and 13 border crossings over all cellular operators, satellite telecommunications and Wi-Fi hotspots within reach. The data collection of this represents more than 40 million data points, and is to date the largest dataset worldwide on hybrid (cellular, Wi-Fi, satellite) connectivity.

The results from this extensive analysis enable Stellar’s customer to accurately model the connectivity environment of its next generation of connected cars. As cars are becoming software-defined, their connectivity becomes an essential part of their operational capabilities. The findings from this study have proven the need for the next generation of cars to benefit from hybrid connectivity, leveraging cellular, Wi-Fi and satellite telecommunications networks. This confirms the Stellar vision of providing a perfect internet on all roads by orchestrating all types of networks, satellites or terrestrial, thanks to its STEER software.

This project follows the success of the STEER SURVEY analysis from the summer of 2023, when Stellar mapped the route of Tour de France, highlighting the alarming state of connectivity along the roads in France. Promptly, as this tool gives all the necessary information to understand the true quality of service for connected car innovations, Stellar has been tasked, by a major European car manufacturer, to map connectivity on roads across several European countries. Major EU roads and border crossings have been assessed, notably addressing the evident connectivity issues at borders, as well as the lack of a stable broadband service and the frequent connection drops when a two-way link cannot be maintained.

STEER SURVEY is a fully-managed service, for comprehensive data insights about connectivity on the move. Stellar maps cellular, Wi-Fi, and satellite quality of service directly from the roads, for Automotive OEMs, Tier-1s, Terrestrial MNOs, satellite operators, and decision-makers in general to know how and where to improve their own connectivity networks or the networks they plan to rely upon for their applications on the move. In practice, STEER SURVEY comes in the form of a dashboard and actionable reports detailing over 50 metrics and parameters related to road connectivity, on the routes requested by Stellar’s customers.

Importantly, STEER SURVEY underlying raw data is used by Stellar to “train” the AI engine of of STEER, the World’s first AI-powered software capable of ensuring that internet-capable devices can seamlessly and predictively switch between, and aggregate, all available cellular, Wi-Fi, and satellite networks.

Stellar is committed to bringing digital life to passengers and vehicles thanks to its innovative solutions. Reach out to business@stellar.tc to explore together with Stellar how to benefit from perfect internet on all roads.

Company website: www.stellar.tc

Press kit: https://www.stellar.tc/pages/press-kit

For further press inquiries: press@stellar.tc

Media Contact
Company Name: Stellar
Contact Person: Media Relations
Email: Send Email
Country: Luxembourg
Website: www.stellar.tc

Key Stocks to Watch: Recent News, Developments and Market Potential KAVL, INBS, GEVI, VTAK, RLYB

As the trading week approaches, now is an opportune moment for investors to delve deeper into companies garnering recent attention. This feature will offer insights into five such stocks. 

Kaival Brands Innovations Group Inc. (NASDAQ: KAVL) has shown robust performance recently, accompanied by a significant increase in trading volume. Since March 20, the stock has surged by 121% and closed at $2.95 per share on April 11, driven by a prolonged short squeeze. On March 27, the company released its financial results for the fiscal year ending January 31, 2024. Quarterly revenues rose to $3.2 million from $2.5 million in the corresponding period last year, mainly due to reduced credits issued to customers. The net loss for the quarter was $2.2 million, marking a decrease from the previous year’s net loss of $3 million. 

Intelligent Bio Solutions Inc. (NASDAQ: INBS), a key player in the medical technology sector, specializes in providing fast, non-invasive, and intelligent testing solutions. Ladenburg Thalmann, a well-known Wall Street institution established in 1876, issued a buy recommendation for Intelligent Bio Solutions Inc. stock, setting a target price of $12 per share. Furthermore, on March 11, the company announced raising $10.1 million through a private placement involving accredited investors in the healthcare sector and institutional investors. On April 11, the company expanded the intellectual property portfolio of its wholly owned subsidiary, Intelligent Fingerprinting Limited, by securing a new European patent with unitary effect for its innovative DSR-Plus Cartridge Reader. 

General Enterprise Ventures Inc. (OTC: GEVI) gained recognition primarily for the advancements made by its subsidiary, Mighty Fire Breaker LLC (MFB), in the field of fire-retardant solutions. In April, it was revealed that Joshua Robinson, the Chief Executive Officer of General Enterprise Ventures Inc., had returned 60% of the company’s outstanding common stock shares to the Treasury, a move expected to significantly enhance shareholder value. On April 2, news surfaced about a collaboration between SkyScout Ai Innovations and MFB’s Value-Add Wildfire Reduction Team, signaling MFB’s entry into the Canadian market with its fire-retardant product CitroTech. 

Catheter Precision Inc. (NYSE American: VTAK) was highlighted in a Ladenburg Thalmann research report on April 5, 2023, with a buy recommendation and a $4 target price for the next year. On April 1, the company reported its Q4 and full fiscal year results for 2023, showing total assets of $30.7 million, a cash balance of $3.6 million, and notable revenue growth compared to the previous year. The company also reduced its net loss in the fourth quarter to $0.7 million from $8.2 million. Additionally, on April 4, Catheter Precision expanded its business development team with industry professionals to drive sales growth and market expansion. 

Rallybio Corporation (NASDAQ: RLYB) gained attention on April 10 following its announcement of a collaboration with Johnson & Johnson (NYSE: JNJ). Under the agreement, Rallybio Corporation will assist in developing complementary therapeutic methods to reduce the risk of FNAIT (fetal and neonatal alloimmune thrombocytopenia). Additionally, Johnson & Johnson Innovations invested $6.6 million in Rallybio Corporation as part of the collaboration.

 

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content.”TSR” is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. “TSR” authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. “TSR” has not been compensated to produce content related to “Any Companies” appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Key Stocks to Watch: Recent News, Developments and Market Potential KAVL, INBS, GEVI, VTAK, RLYB

Ituran Increases Dividend To 6% After Posting Record-Setting 2023 Operational Performance ($ITRN)

Ituran Location and Control (NASDAQ: ITRN) presents a compelling investment proposition. In fact, with a forward-looking dividend yield of 6%, this innovative technology company, which averages roughly 57,000 shares traded daily, may present a value disconnect too wide to ignore. That’s not an overly aggressive assessment, either. Considering this company posted record across-the-board financial metrics, including a 9% revenue increase in year-over-year to $320 million, net income of $48 million, an increase of 30% year-over-year, and a 10% increase in EBITDA to $87 million, ITRN’s market cap of $530 million, while impressive by most listing standards, may actually fall short of an appropriate fair value.

An analyst at Barclay’s covering ITRN stock makes that case, modeling a 12-month price target for ITRN shares to reach $35, over 30% higher than its current price. That expectation is bullish but not overly so. In addition to its record revenues, the company also generated $77 million in FY2023 operating cash flow as it continues to earn deals from global companies interested in its revolutionary telematics and connected car ecosystem. The interest is warranted. While some of ITRN’s competitors do one of two things well, Ituran does many by leveraging strength from a full spectrum of innovative software solutions, in-vehicle sensors, and unique services and system functionality that do more than address challenges; they overcome them.

That distinction can do more than drive revenues higher from already record levels; it also supports the evidence-based case that the path of least resistance for ITRN shares is currently paved higher.

Ituran is Ushering in the Shift in Mobility Technology 

The bullish expectation is justified, especially as Ituran continues strengthening its leadership position in the emerging mobility technology field by providing value-added location-based services, particularly its full suite of services for the modern connected car. While under the radar of investors, that’s not the case from a client-and-use perspective.

Served by its 2,800 employees from offices worldwide, Ituran is the largest OEM telematics provider in Latin America, with its products and applications used by customers in over 20 countries. And a lot of them. By the end of 2023, subscribers wanting Ituran products and services reached almost 2.3 million subscribers increasing by 186,000 during the year and meeting growth guidance despite the challenging economic and geopolitical market landscapes.

In addition to scoring record operating performances, Ituran ended the year financially solid, with year-end net cash and marketable securities of $53 million. Here’s the better news from those investors liking to get “paid to wait” for growth. In Q4, Ituran added to its dividend distribution accounts and bought back over $6.6 million in shares, representing a 6% passive income yield and a value driver from a forward-looking valuation perspective, respectively. The latter is significant, considering that the company only has about 20 million shares outstanding on a fully diluted basis.

Operating Momentum After an Impressive Q4/2023

Attracting investors and supporting the bullish analyst model is that year-end results were strengthened by an impressive Q4. For the period, net subscriber growth, meaning recurring revenue stream providers, increased by 42,000 when combining the new aftermarket subscribers of 38,000 with the net increase in OEM subscribers of 4,000. Revenues increased by 4% to $78 million, leading to net income of $12 million, 26% higher than a year ago. The performance prompted the Board to increase the dividend policy by 60% to $8 million for the quarter, a run rate of $32 million per year, based on the growing profitability and strong operating cash flow.

It also led to optimistic guidance about expectations in 2024. Management said it expects to add approximately 35,000 to 40,000 net new subscribers each quarter during 2024, contributing to EBITDA projections between $90-95 million. In 2025, EBITDA is targeted to surpass $100 million. Management did note that these targets are based on current exchange rates and assume that Israel’s current global macroeconomic situation and political situation do not significantly change. Still, if Mid-East tensions ease, the potential to beat is undoubtedly in play, noting the company’s business resilience during challenging times.

Keep in mind that hardware installations and, therefore, product revenues were paused for at least several weeks following the outbreak of war in Israel on October 7. That caused some declines in a quarterly comparison. However, year-over-year, Ituran accomplished what it and investors want and appreciate- growth. Better still, despite supply-chain issues, gross margins stayed impressive, with subscription revenues at around 58%, and the gross margin on products at 22%. That facilitated Q4 operating income to increase by 8% to $16.5 million compared to $15.3 million in the fourth quarter of last year.

Value Drivers are Active in 2024

From an investor perspective, financial results, interim project updates, and 2024 guidance have guided expectations for the Ituran growth spurt to continue. And the best news from that same standpoint is that the company shares the wealth earned. In addition to the increased dividend, the company will continue its previously announced $25 million share buy-back program, which increased to $35 million, last February. With roughly $6.7 million remaining under that authorization, it’s more than support at the bid; it’s a value driver that can steepen the growth curve trajectory when new milestones are reached.

And there could be many contributing factors. During its recent earnings conference call, ITRN noted that value drivers accrue from different segments, including those created by insurance companies and car owners, especially in Israel, who are looking for effective security systems to protect assets. Because Ituran solutions are considered best-in-class in many respects, it can leverage that distinction and add to already appreciating levels of subscriber growth.

In other countries, Ituran is focused on monetizing market opportunities on the B2B side, working with financial institutions to offer asset protection and security solutions when they provide loans to new car buyers. In Latin America, where there has been an increase in car theft and damage from violence, the company is focused on penetrating those markets more quickly this year to exploit that revenue-generating market opportunity and add traction to its goal of surpassing $100 million in 2025 EBIDTA. That goal is within reach.

Remember, the subscriber base is growing at 9%. And with upsells for its products more the norm than the exception, tracking higher to meet that projection is more than just an ambitious target; it’s in the company’s crosshairs. Coupled with financial efficiencies, a management team committed to ensuring revenues fall faster to its bottom line, and increasing global demand for the kinds of security solutions Ituran provides, this dividend-bearing stock looks very attractive at current levels, even more so with a 6% yield, which could also move higher if guidance is met. In other words, investors could earn while they earn, which may be the ultimate win-win investment proposition.

 

Disclaimers: This content has been created by Hawk Point Media Group, Llc. (HPM) and is responsible for the production and distribution of this content. This presentation should be considered and explicitly regarded as sponsored content. Hawk Point Media Group, LLC. has been compensated twenty-thousand-dollars to create this content as part of a more extensive digital marketing program by an unrelated third party of the company. Accordingly, this content may be used and syndicated beyond the channels used by Hawk Point Media, Llc. This disclaimer and the link to the broader disclosures must be part of all reproductions. That compensation creates a conflict of interest because the content presented may only provide a favorable viewpoint of the company featured. The contributors do NOT buy and sell securities before and after any article, report, or publication. HPM holds ZERO shares and has never owned stock in Ituran Location and Control Ltd. The information in this video, article, and related newsletters is not intended to be, nor does it constitute, investment advice or recommendations. Hawk Point Media Group, Llc. strongly urges you to conduct a complete and independent investigation of the respective companies and consider all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. Never take opinions, articles presented, or content provided as the sole reason to invest in any featured company. Investors must always perform their own due diligence before investing in any publicly traded company and understand the risks involved, including losing their entire investment. For the complete disclosure statement, including compensation received, click HERE.

Media Contact
Company Name: Hawk Point Media
Contact Person: Editorial Dept.
Email: info@hawkpointmedia.com
Country: United States
Website: https://ituran.com/ituranglobal/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Ituran Increases Dividend To 6% After Posting Record-Setting 2023 Operational Performance ($ITRN)

Exploring Digital Currency Trading Platforms Suitable for Novice Investors in Indonesia

In the current wave of digitalization, interest in digital asset investment is continuously rising. However, for novice investors, understanding the basic principles of digital currencies and their price fluctuations is crucial before entering the field of cryptocurrency trading or capital investment. Moreover, selecting the right digital currency trading platform is a critical first step for novice investors when starting cryptocurrency trading. Choosing a platform that is both stable and secure is essential. In Indonesia, there are many such trading platforms available.

 

Faced with a wide array of digital currency applications on the market, new traders or investors may feel overwhelmed. Choosing a platform that is feature-rich, user-friendly, and provides transaction fee discounts for each trade is particularly important.

Here is a guide from Coinspeaker. The list of digital currency trading platforms in Indonesia includes:

1. PT Aset Digital Berkat (Tokocrypto)

2. PT Aset Kripto Internasional (NVX)

3. PT Bumi Sentosa Cemerlang (Pluang)

4. PT Coinbit Digital Indonesia (Stockbit Crypto)

5. PT Indodax Nasional Indonesia (Indodax)

6. PT Gudang Kripto Indonesia (Gudang Kripto)

7. PT Galad Koin Indonesia (Galad)

8. PT Cipta Koin Digital (Naga)

9. PT CTXG Indonesia Berkarya (Mobee)

10. PT Kagum Teknologi Indonesia (Ajaib Kripto)

11. PT Rekeningku Dotcom Indonesia (REKU)

12. PT Sentra Bitwewe Indonesia (Bitwewe)

13. PT Tumbuh Bersama Nano (Nanovest)

14. PT ZUHYX Exchange Indonesia (ZUHYX)

15. PT Tiga Inti Utama (Triv)

16. PT Luno Indonesia LTD (Luno)

17. PT Upbit Exchange Indonesia (Upbit)

18. PT Pintu Kemana Saja (Pintu)

19. PT Kripto Maksima Koin (KMK)

20. PT Cyrameta Exchange Indonesia (Cyra)

21. PT Zipmex Exchange Indonesia (Zipmex)

22. PT Indonesia Digital Exchange (DEX)

23. PT PT Mitra Kripto Sukses (MKS)

24. PT Utama Aset Digital (Bittime)

25. PT Pedagang Aset Kripto (PAK)

26. PT Ventura Koin Nusantara (Vonix)

27. PT Gerbang Aset Digital (Fasset)

Disclaimer: This press release may contain forward-looking statements. Forward-looking statements describe future expectations, plans, results, or strategies (including product offerings, regulatory plans and business plans) and may change without notice. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements.

Media Contact
Company Name: Coinspeaker
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: https://www.coinspeaker.com/

Joseph Samuels of Iset Capital Initiates Prestigious Grant to Elevate Aspiring Musical Theater Artists Nationwide

In a move to cultivate and celebrate emerging talent in the vibrant world of musical theater, Joseph Samuels, esteemed financial strategist and arts advocate, has launched the highly anticipated Joseph Samuels Grant for Musical Theater. This groundbreaking initiative is poised to provide invaluable support and recognition to individuals who harbor a deep passion for musical theater and demonstrate unwavering dedication to artistic excellence.

The Joseph Samuels Grant for Musical Theater, boasting a substantial fund of $1,000, stands as a beacon of hope and opportunity for aspiring artists across the nation. Open to undergraduate students from all corners of the country, this esteemed grant endeavors to propel talented individuals towards realizing their dreams in the competitive landscape of musical theater.

With its diverse array of eligible applicants including playwrights, composers, lyricists, directors, choreographers, performers, and other creative visionaries, the Joseph Samuels Grant for Musical Theater embraces the richness of artistic expression within the realm of musical storytelling. Joseph Samuels, the visionary architect behind this philanthropic endeavor, brings to bear his wealth of experience and expertise as the founder of Islet Capital Management, a leading financial institution renowned for its commitment to innovation and excellence.

A product of Rutgers University–New Brunswick, where he earned a Bachelor of Arts in Economics, Joseph Samuels’ journey from the halls of academia to the pinnacle of the financial world has been marked by a profound appreciation for the arts. His passion for fostering creativity and empowering individuals to pursue their dreams serves as the driving force behind the establishment of this transformative grant.

In envisioning the Joseph Samuels Grant for Musical Theater, Joseph Samuels seeks to bridge the gap between the worlds of finance and the arts, recognizing the symbiotic relationship between financial support and artistic innovation. Through this grant, he endeavors to provide aspiring artists with the resources and encouragement they need to embark on their journey towards artistic fulfillment and professional success.

Applicants for the Joseph Samuels Grant for Musical Theater are invited to submit compelling essays reflecting on their personal journey, their profound passion for musical theater, and their vision for the future. Each applicant is encouraged to articulate how the grant would serve as a catalyst for their artistic growth and development, outlining their aspirations, goals, and the impact they hope to make within the industry.

The application deadline for the Joseph Samuels Grant for Musical Theater is December 15, 2024. Following a rigorous review process, the winner will be announced on January 15, 2025, heralding the dawn of a new chapter in their artistic journey.

For further details and to submit your application, please visit the official website of the Joseph Samuels Grant for Musical Theater: https://josephsamuelsgrant.com/.

About

Joseph Samuels, a visionary leader and philanthropist, is the driving force behind the Joseph Samuels Grant for Musical Theater. With a profound commitment to fostering creativity and nurturing emerging talent, Joseph Samuels seeks to empower aspiring artists to pursue their dreams in the competitive world of musical theater. Through his innovative approach and unwavering dedication, Joseph Samuels aims to bridge the gap between finance and the arts, creating opportunities for artistic expression and cultural enrichment. Join us in celebrating the transformative power of musical theater and the vision of Joseph Samuels.

Media Contact
Company Name: Joseph Samuels Grant
Contact Person: Joseph Samuels
Email: Send Email
City: New York
State: New York
Country: United States
Website: https://josephsamuelsgrant.com

Dr. Paul Carey DDS Scholarship: Fostering Excellence and Compassion in Healthcare

Dr. Paul Carey DDS Scholarship: Fostering Excellence and Compassion in Healthcare

Dr. Paul Carey DDS

Massapequa, NY – The Dr. Paul Carey Scholarship for Medical Students is delighted to announce the commencement of its annual scholarship program, offering a one-time award of $1,000 to support the academic endeavors of promising medical professionals. Established in tribute to Dr. Paul Carey, D.D.S., this esteemed scholarship epitomizes a dedication to academic prowess, patient-centered care, and the advancement of healthcare practices.

The scholarship is open to undergraduate students worldwide who are currently enrolled or have been accepted into accredited medical programs. It is designed to honor individuals who reflect Dr. Carey’s unwavering commitment to academic excellence and compassionate healthcare. Applicants are encouraged to submit a meticulously crafted essay in response to the following prompt: “Reflect on a transformative healthcare experience that has influenced your journey and discuss how it has shaped your aspirations to make a difference in the field.”

Dr. Paul Carey’s illustrious career is marked by a relentless pursuit of knowledge and expertise. A distinguished graduate of Fairfield University and N.Y.U College of Dentistry, Dr. Carey’s journey embodies the epitome of dedication and passion in the field of dentistry. Over the span of 38 years, his contributions as a faculty member at N.Y.U, where he taught Advanced Restorative Techniques, underscore his commitment to academic excellence and mentorship, shaping the future of healthcare professionals.

Applicants for the Dr. Paul Carey Scholarship are expected to demonstrate exceptional academic achievements, a profound commitment to the healthcare sector, and submit an engaging essay that articulates their transformative healthcare experiences. The submission deadline for applications is December 15, 2024, with the scholarship recipient set to be announced on January 15, 2025.

To apply, interested candidates must submit their essay along with their full name, contact information, and proof of enrollment or acceptance to apply@drpaulcareyscholarship.com.

The Dr. Paul Carey Scholarship aspires to empower the next generation of medical leaders by providing financial support and recognition for their outstanding accomplishments. Through this annual essay contest, the scholarship seeks to identify individuals who share Dr. Carey’s vision of excellence and compassion in healthcare, nurturing their potential to make a profound impact in the field.

For comprehensive details regarding the scholarship program, application process, and opportunities for engagement, please visit the official website at https://drpaulcareyscholarship.com/

About Dr. Paul Carey

Dr. Paul Carey, D.D.S., is a distinguished graduate of Fairfield University and N.Y.U College of Dentistry, with over 38 years of dedicated service in dentistry. His specialization in endodontics and proficiency in prosthetic implant technology have garnered him acclaim within the Massapequa community and beyond. The Dr. Paul Carey Scholarship stands as a testament to his enduring legacy, striving to support and inspire the next generation of healthcare professionals in their pursuit of excellence and compassion.

Media Contact
Company Name: Dr. Paul Carey Scholarship
Contact Person: Dr. Paul Carey DDS
Email: Send Email
City: Massapequa
State: New York
Country: United States
Website: https://drpaulcareyscholarship.com